Hepatitis C virus infection and the dialysis patient

Fabrizio Fabrizi, Giovanna Lunghi, Sri Venkatesh Ganeshan, Paul Martin, Piergiorgio Messa

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) remains common in patients undergoing regular dialysis and is an important cause of liver disease in this population both during dialysis and after renal transplantation (RT). Anti-HCV screening of blood products has almost eliminated posttransfusion HCV infection but acquisition of HCV continues to occur in dialysis patients because of nosocomial spread. The natural history of HCV in dialysis population is not completely understood though recent data show that HCV infection has a detrimental role on survival of chronic dialysis patients. Several clinical trials have suggested that the response rate to conventional interferon (IFN) is higher in dialysis patients than those with normal kidney function but tolerance is lower. There are only limited data about pegylated IFN alone or in association with ribavirin for hepatitis C in dialysis population. IFN remains contraindicated post-RT because of concern about precipitating graft dysfunction; however, preliminary evidence shows the durability of sustained response to antiviral therapy pre-RT after renal transplant. Successful pretransplant therapy is associated with several benefits after RT including reduced incidence of posttransplant diabetes mellitus and de novo glomerulonephritis in HCV-infected recipients.

Original languageEnglish
Pages (from-to)416-422
Number of pages7
JournalSeminars in Dialysis
Volume20
Issue number5
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

Virus Diseases
Hepacivirus
Dialysis
Kidney Transplantation
Interferons
Population
Transplants
Kidney
Ribavirin
Hepatitis C
Glomerulonephritis
Natural History
Antiviral Agents
Liver Diseases
Diabetes Mellitus
Clinical Trials
Survival
Incidence
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Hepatitis C virus infection and the dialysis patient. / Fabrizi, Fabrizio; Lunghi, Giovanna; Ganeshan, Sri Venkatesh; Martin, Paul; Messa, Piergiorgio.

In: Seminars in Dialysis, Vol. 20, No. 5, 01.09.2007, p. 416-422.

Research output: Contribution to journalArticle

Fabrizi, F, Lunghi, G, Ganeshan, SV, Martin, P & Messa, P 2007, 'Hepatitis C virus infection and the dialysis patient', Seminars in Dialysis, vol. 20, no. 5, pp. 416-422. https://doi.org/10.1111/j.1525-139X.2007.00311.x
Fabrizi, Fabrizio ; Lunghi, Giovanna ; Ganeshan, Sri Venkatesh ; Martin, Paul ; Messa, Piergiorgio. / Hepatitis C virus infection and the dialysis patient. In: Seminars in Dialysis. 2007 ; Vol. 20, No. 5. pp. 416-422.
@article{c69047707cef4f37a572d9e4c8ac42fe,
title = "Hepatitis C virus infection and the dialysis patient",
abstract = "Hepatitis C virus (HCV) remains common in patients undergoing regular dialysis and is an important cause of liver disease in this population both during dialysis and after renal transplantation (RT). Anti-HCV screening of blood products has almost eliminated posttransfusion HCV infection but acquisition of HCV continues to occur in dialysis patients because of nosocomial spread. The natural history of HCV in dialysis population is not completely understood though recent data show that HCV infection has a detrimental role on survival of chronic dialysis patients. Several clinical trials have suggested that the response rate to conventional interferon (IFN) is higher in dialysis patients than those with normal kidney function but tolerance is lower. There are only limited data about pegylated IFN alone or in association with ribavirin for hepatitis C in dialysis population. IFN remains contraindicated post-RT because of concern about precipitating graft dysfunction; however, preliminary evidence shows the durability of sustained response to antiviral therapy pre-RT after renal transplant. Successful pretransplant therapy is associated with several benefits after RT including reduced incidence of posttransplant diabetes mellitus and de novo glomerulonephritis in HCV-infected recipients.",
author = "Fabrizio Fabrizi and Giovanna Lunghi and Ganeshan, {Sri Venkatesh} and Paul Martin and Piergiorgio Messa",
year = "2007",
month = "9",
day = "1",
doi = "10.1111/j.1525-139X.2007.00311.x",
language = "English",
volume = "20",
pages = "416--422",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Hepatitis C virus infection and the dialysis patient

AU - Fabrizi, Fabrizio

AU - Lunghi, Giovanna

AU - Ganeshan, Sri Venkatesh

AU - Martin, Paul

AU - Messa, Piergiorgio

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Hepatitis C virus (HCV) remains common in patients undergoing regular dialysis and is an important cause of liver disease in this population both during dialysis and after renal transplantation (RT). Anti-HCV screening of blood products has almost eliminated posttransfusion HCV infection but acquisition of HCV continues to occur in dialysis patients because of nosocomial spread. The natural history of HCV in dialysis population is not completely understood though recent data show that HCV infection has a detrimental role on survival of chronic dialysis patients. Several clinical trials have suggested that the response rate to conventional interferon (IFN) is higher in dialysis patients than those with normal kidney function but tolerance is lower. There are only limited data about pegylated IFN alone or in association with ribavirin for hepatitis C in dialysis population. IFN remains contraindicated post-RT because of concern about precipitating graft dysfunction; however, preliminary evidence shows the durability of sustained response to antiviral therapy pre-RT after renal transplant. Successful pretransplant therapy is associated with several benefits after RT including reduced incidence of posttransplant diabetes mellitus and de novo glomerulonephritis in HCV-infected recipients.

AB - Hepatitis C virus (HCV) remains common in patients undergoing regular dialysis and is an important cause of liver disease in this population both during dialysis and after renal transplantation (RT). Anti-HCV screening of blood products has almost eliminated posttransfusion HCV infection but acquisition of HCV continues to occur in dialysis patients because of nosocomial spread. The natural history of HCV in dialysis population is not completely understood though recent data show that HCV infection has a detrimental role on survival of chronic dialysis patients. Several clinical trials have suggested that the response rate to conventional interferon (IFN) is higher in dialysis patients than those with normal kidney function but tolerance is lower. There are only limited data about pegylated IFN alone or in association with ribavirin for hepatitis C in dialysis population. IFN remains contraindicated post-RT because of concern about precipitating graft dysfunction; however, preliminary evidence shows the durability of sustained response to antiviral therapy pre-RT after renal transplant. Successful pretransplant therapy is associated with several benefits after RT including reduced incidence of posttransplant diabetes mellitus and de novo glomerulonephritis in HCV-infected recipients.

UR - http://www.scopus.com/inward/record.url?scp=34748895561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748895561&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2007.00311.x

DO - 10.1111/j.1525-139X.2007.00311.x

M3 - Article

VL - 20

SP - 416

EP - 422

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 5

ER -